Charles River Laboratories (CRL) Stock
Global lab services provider for drug development. Here's the price, business snapshot, and what's worth knowing about Charles River Laboratories in June 2026.
Charles River Laboratories (CRL) provides a wide range of research models, preclinical and clinical laboratory services to pharmaceutical, biotechnology and academic customers. The firm supports drug discovery and development with animal models, safety assessment, biologics testing and specialised lab services that help clients progress candidates from discovery to market. Outsourcing trends, rising R&D spending by biopharma, and growth in biologics and cell & gene therapies are structural drivers often cited by investors. CRL’s scale and global footprint can offer cross-border service continuity, though earnings are sensitive to industry R&D cycles, regulatory changes and ethical or reputational issues around animal research. The company’s mid-cap market capitalisation (about $9.27bn) places it among larger contract research providers but competition and integration of acquisitions are ongoing considerations. This summary is educational only; it isn’t investment advice. Investors should assess their own goals, risk tolerance and check up-to-date company filings and market data before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Charles River Laboratories' stock, aiming for a target price of $205.71.
Financial Health
Charles River Laboratories is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CRL
U.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPersonal Care Safety: Could Talc Verdict Boost Stocks?
A record $1.5 billion verdict against Johnson & Johnson in a talc cancer case highlights the immense legal and financial risks associated with certain consumer product ingredients. This creates a compelling investment opportunity in companies that provide safer, alternative materials and advanced testing services for the personal care industry.
Published: 24 December 2025
Explore BasketClinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketGarage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Outsourcing Tailwinds
Pharmaceutical firms increasingly outsource specialist testing and models, which can support demand for CRL’s services — though demand may fluctuate with R&D budgets.
Global Service Footprint
A broad international network helps serve multinational clients and diversify revenue, but global regulation and integration risks persist.
Biologics & Innovation
Growth in biologics, cell and gene therapies can create higher-value testing needs that favour specialists, although technological and regulatory shifts bring uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
